Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today published its 2026 Impact Report, highlighting the Company’s sustainability, social and governance strategy, initiatives and performance. The annual report showcases how the Company continues to translate innovation into real-world impact, while embedding responsible and sustainable practices through its operations.

"At Revvity, we believe scientific innovation and responsible business practices go hand in hand," said Prahlad Singh, president and chief executive officer at Revvity. "We are proud of the progress we've made advancing our environmental, social and governance priorities, from strengthening transparency and environmental stewardship to expanding access to healthcare and investing in our people and communities."

The 2026 Impact Report highlights the Company’s key achievements, including:

• Disclosing material Scope 3 emissions for the first time, which marks an expansion of the Company’s sustainability reporting.
• Reducing carbon footprint by lowering Scope 1 and 2 greenhouse gas emissions by 1.3% in 2025 (16% total reduction from the 2022 baseline).
• Achieving a 49% non-hazardous diversion rate, surpassing the Company’s annual goal of 40%.
• Advanced talent retention and workforce development initiatives, reducing voluntary turnover to 7% from 9% and filling 24% of open roles through internal promotions and transfers.
• Launching the Revvity Supports Research (RSR) initiative, which provides general research grants totaling $180,000 to 12 key academic institutions whose work aligns with the scientific areas the Company supports.

To learn more about Revvity’s commitments and progress, visit esg.revvity.com.

About Revvity

At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.